Ghanshyam Teli

Email: tghanshyam203@gmail.com

Mobile No: +91-9783150846

Current location: Bhilwara, Rajasthan, 311001, India.

SUMMARY

I am working as an Assistant Professor at the School of Pharmacy, Sangam University, Bhilwara, for the last 1.8 years. I have 1 year of experience as a Junior Research Fellow at Acharya and B.M. Reddy College of Pharmacy, Bengaluru, and 13 months of experience at United Biotech Pvt Ltd as Assistant R&D Chemist. I worked on various projects such as synthesizing 4-Thiazolidinone derivatives, PEGAsparaginase, PLGA, Amoxicillin sodium, SBE-Beta-CD, and Paclitaxel-HSA complex. I have good skills in multi-step synthesis. I am willing to work in an educational department where I can share my knowledge with students in an engaging way. Seeking an opportunity for professional growth and increasing responsibility. I want to expand my knowledge and upgrade my skills in a fruit-filled environment.

ACADEMIC QUALIFICATIONS

Course	Board/University	Year of passing	Percentage
Ph.D.	Baba Farid University of Health Sciences	Pursuing	
M. Pharmacy	ISF College of Pharmacy	2021	82%
B. Pharmacy	Geetanjali University	2019	73.7%
12th class	RBSE	2013	67.60%
10th class	RBSE	2011	63.50%

Projects

- Design, synthesis, and biological evaluation of 4-thiazolidinone conjugates as anti-breast cancer agents.
- Discovery of triangular heterocyclic molecules as inhibitors of dual oncogenic pathways triggered by HSP90 and BRAF kinase.

Experience

- From 1.8 years, working as Assistant Professor at School of Pharmacy, Sangam University, Bhilwara, Rajasthan, India.
- 13 months of industrial experience as an assistant R&D chemist

- 1 year experience as a Junior Research Fellow (JRF)

PROFESSIONAL SKILLS

- Practical knowledge in conducting and performing chemical synthesis.
- Characterization of synthesized compounds by UV, IR Spectroscopy, ^{1}H NMR
- Can carry out docking studies and ADMET properties.
- Ability to work in a team and decision making
- Problem-solving and leadership quality

TECHNICAL SKILLS

- The Basic knowledge of computer application software: MS Office, ChemDraw, Autodock, Molegro virtual docker (MVD), Pymol, Discovery studio.
- Well-versed in handling instruments like Flash Chromatography, Column Chromatography, Rota-evaporator, Vacuum dryer, UV-Vis Spectrophotometer, pH meter, Melting point, and Cooling centrifuge.

PUBLICATIONS

RESEARCH ARTICLES

- **Teli G**, Sharma P, Chawla PA. Exploring the potential of substituted 4-thiazolidinone in the treatment of breast cancer: Synthesis, biological screening and *in silico* studies. Polycyclic Aromatic Compounds. 2022, 23: 1-33. https://doi.org/10.1080/10406638.2022.2112708. **IF – 2.4**
- Archna, Chawla PA, **Teli G**, Pathania S, Singh S, Srivastava V. Exploration of Antioxidant, Anti-inflammatory and Anticancer Potential of Substituted 4-Thiazolidinone Derivatives: Synthesis, Biological Evaluation and Docking Studies. Polycyclic Aromatic Compounds. 2022; 16:1-22. DOI: https://doi.org/10.1080/10406638.2021.2019796**. IF – 2.4**
- Srivastava P, **Teli G**, Chawla PA. Synthesis and Characterization of Nitrogen Containing Heterocyclic Derivatives of 1,3-Thiazolidine-2,4-Diones as Dual Anti-Inflammatory and Anti-Oxidant Agents and Their Docking Studies. Letters in Drug Design & Discovery. 2022, volume 19. http://dx.doi.org/10.2174/1570180819666220523142245. **IF – 1.2**
- Pal R, **Teli G**, Sharma B. In-vitro anti-inflammatory and antioxidant activity of Nephrolepis cordifolia and molecular docking of its active chemical constituents. Pharmaspire 2021; 13(1): 21-27.
- Varshney MM, **Teli G**, Chawla P, Hussain A. Synthesis, characterization, in vitro antimicrobial and anti-inflammatory evaluations of {5'-(substituted aryl)-2-furanyl}-3, 4dihydro-1h-pyrimidine-2-one derivatives. Anti-Infective Agents. Indian drugs. 2023; 60(03):17. https://doi.org/10.53879/id.60.03.13669

- Pal R, Matada GS, **Teli G**, Chawla PA, Chawla V. Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/ hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: *In-vitro*

and *in-silico* exploration**.** Journal of Molecular Structure. 2025: 1327(2025): 141227. DOI: https://doi.org/10.1016/j.molstruc.2024.141227. **IF – 4.0**

- Pal R, Matada GS, **Teli G**. Integrated Computational and Experimental Insights into MEK1/2 Inhibitors: Structural Validation, Docking, ADMET, Molecular Dynamics, and Anticancer Evaluation. Chemistry & Biodiversity.:e202402907. DOI: https://doi.org/10.1002/cbdv.202402907. **IF – 2.3**
- Pal R, Matada GS, Teli G, Akhtar MJ, Kumar B. Design, Synthesis, and Molecular Profiling of Pyrimidine-Furan Derivatives Targeting EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation. Chemistry & Biodiversity.:e202500549. DOI: https://doi.org/10.1002/cbdv.202500549. **IF – 2.3**

REVIEW ARTICLES

- **Teli G,** Pal R, Maji L, Purawarga Matada GS, Sengupta S. Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinase**.** Journal of Biomolecular Structure and Dynamics. 2023; 26: 1-33. **IF – 2.7**

  http://doi.one/10.1080/07391102.2023.2205943
- **Teli G**, Chawla PA. Hybridization of Imidazole with Various Heterocycles in Targeting Cancer: A Decade's Work. ChemistrySelect. 2021, 20;6(19):4803-36. DOI: https://doi.org/10.1002/slct.202101038. **IF – 1.9**
- Chawla P, **Teli G**, Gill RK, Narang RK. An Insight into Synthetic Strategies and Recent Developments of Dihydrofolate Reductase Inhibitors. ChemistrySelect. 2021, 22;6(43): 12101-12145. DOI: https://doi.org/10.1002/slct.202102555. **IF – 1.9**
- Pal R, **Teli G**, Purawarga Matada GS, Dhiwar PS. Designing streategy, structural activity relationships and biological activity of recently develop heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibtiors. Journal of Molecular Structure. 2023; 136021. https://doi.org/10.1016/j.molstruc.2023.136021.**IF – 4.0**
- Pal R, **Teli G**, Purawarga Matada G S. Nitrogen containing heterocyclic scaffolds as EGFR inhibitors: designing approaches, molecular docking, and SAR. ChemistrySelect. 2023;8(26): e202301200. https://doi.org/10.1002/slct.202301200. **IF – 1.9**
- Pal R, **Teli G**, Akhtar MJ, Purawarga Matada GS. The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis. 2023, European Journal of Medicinal Chemistry. 2023, 258:115609. https://doi.org/10.1016/j.ejmech.2023.115609. **IF – 6.0**
- Sharma D, **Teli G**, Gupta K, Bansal G, Chawla PA. Nano-Biosensors from Agriculture to Nextgen Diagnostic Tools. Current Nanomaterials. 2022;7(2): 110-38. DOI: https://doi.org/10.2174/2405461507666220131104843
- Negi M, Chawla PA, **Teli G**, Faruk A, Chawla V. Molnupiravir – A prospective silver bullet to mitigate severe acute respiratory syndrome corona virus-2. Pharmaspire 2021; 13(1): 7785.
- **Teli G**, Pal R, Bisht H. A comprehensive review: Coronavirus disease 2019 (COVID-19). IJSDR. 2020;5(9). DOI: http://doi.one/10.1729/Journal.24618

- Maji L, **Teli G**, Raghavendra NM, Sengupta S, Pal R, Ghara A, Matada GS. An updated literature on BRAF inhibitors (2018–2023). Molecular Diversity. 2023 Jul 20:1-42. DOI: https://doi.org/10.1007/s11030-023-10699-3. **IF-3.9.**
- **Teli G**, Pal R, Maji L, Sengupta S, Raghavendra NM, Matada GS. Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure-Activity Relationship. Chemistry & Biodiversity. 2023 Sep;20(9):e202300515. DOI: https://doi.org/10.1002/cbdv.202300515. **IF – 2.3**
- Pal R, **Teli G**, Sengupta S, Maji L, Purawarga Matada GS. An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC). Journal of Biomolecular Structure and Dynamics. 2023 Aug 24:1-7. DOI: https://doi.org/10.1080/07391102.2023.2252082. **IF – 2.7.**
- Pal R,**Teli G**, Akhtar MJ, Matada GS. Synthetic product-based approach toward potential antileishmanial drug development. European Journal of Medicinal Chemistry. 2024 Jan 5, 263:115927. DOI: https://doi.org/10.1016/j.ejmech.2023.115927. **IF – 6.0**
- Pal R, Matada GS, **Teli G**, Saha M, Patel R. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship. Bioorganic Chemistry. 2024 Aug 8:107696. DOI: https://doi.org/10.1016/j.bioorg.2024.107696. **IF-4.5.**
- **Teli G**, Maji L, Pal R, Maheshwari N, Matada GS, Chawla PA, Chawla V. Recent advancements in mechanistic Research, therapeutic Potential, and Structure-Activity relationships of Aurora kinase inhibitors in cancer therapies. Bioorganic Chemistry. 2024 Nov 16:107976. DOI: https://doi.org/10.1016/j.bioorg.2024.107976. **IF-4.5.**
- Maji L, Sengupta S, Purawarga Matada GS, **Teli G**, Biswas G, Das PK, Panduranga Mudgal M. Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure-activity relationship. Molecular diversity. 2024 Jan 18, 28: 4467–4513. DOI: https://doi.org/10.1007/s11030-023-10794-5. **IF-3.9.**
- Sengupta S, Maji L, Das P K, **Teli G**, Nag M, Khan N, Haque M, Purawarga Matada GS. Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure-activity relationship. Molecular Diversity. 2025 Jan 30: 1-31. DOI: https://doi.org/10.1007/s11030-024-11091-5. **IF-3.9.**
-

BOOK CHAPTERS

- Raghavendra NM, Kumar BP, Sasmal P, **Teli G**, Pal R, Gurubasavaraja Swamy PM, Sajeev Kumar B. Designing Studies in Pharmaceutical and Medicinal Chemistry. InThe Quintessence of Basic and Clinical Research and Scientific Publishing 2023 Oct 1 (pp. 125-148). Singapore: Springer Nature Singapore. DOI: https://doi.org/10.1007/978-981-99-1284-1_9
- Pal R, Purawarga Matada GS, **Teli G**, Hosamani KR, Kuamrswamy B, Aayishamma I, MD Ashadul Sk, Viji MP. Repositioning of Drugs in Non-Small Cell Lung Cancer: Old Weapons

for a New War. Drug Repurposing: Novel Therapeutic Avenues and Innovations in Healthcare. NOVA science publishers, New York, USA. 2025 Mar 3: 123-148.
DOI: https://doi.org/10.52305/ZKEA0671

AWARDS

- GPAT qualified, 2019.
- Received PG Fellowship from AICTE during August 2019 – June 2021 for M.Pharm.
- Got certificate of poster presentation/ Participating in conferences/Webinar:
    - Participated in Five Days International Faculty Development Programme on Cutting-edge Developments and Future Directions in Pharmaceutical & Health Sciences, Organized by School of Pharmacy, Sharda University, Greater Noida.
    - Attained Two Days Online Cloud-Based Workshop on "Computational Drug Design Approaches" In Collaboration with Schrodinger India Pvt. Ltd., Organized by The Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard University.
    - Participated in NEP 2020 Orientation & Sensitization Programme under Malaviya Mission Teacher Training Programme (MM-TTP) of UGC Organized by Malaviya Mission Teacher Training Centre, Devi Ahilya Vishwavidyalaya, Indore.
    - Attained Workshop on Computer-Aided Drug Design Organized by ISF College of Pharmacy.
    - Participated National Webinar on NDMA Impurity in Medicine: A Source of Bewilderment for the Patients Organized by SPER.
    - Attained National Seminar on Intellectual Property Rights in collaboration with SPER-Punjab State Branch, Organized by ISF College of Pharmacy.
    - Attained conference of The Indian Hospital Pharmacists' Association on Safe & Effective Medicines for All Organized by ISF College of Pharmacy.
    - Attained One Day International Workshop on Lung Injury: Challenge for Therapy & Emerging Possibilities in collaboration with SPER, Organized by ISF College of Pharmacy.
    - Entitled Colon Targeted Drug Delivery System the Conference Sponsored by DBT and ICMR.
    - Entitled pH Sensitive Nano Drug Delivery System at the Conference Sponsored by DBT, ICMR, and APTI.
    - Entitled An Innovative and Emerging Technology Buccal Film Drug Delivery at the Conference Sponsored by ICMR and Organized by Geetanjali Institute of Pharmacy, Geetanjali University.
    - Entitled Central of Pain in Cancer Patients at the conference sponsored by DST and Organized by Geetanjali Institute of Pharmacy, Geetanjali University.

PERSONAL DETAILS

Name- Ghanshyam Teli

Father's name- S. Jagdish Chandra Teli
Date of birth- May 12, 1995
Nationality- Indian
Sex- Male
Language- English, Hindi.
Address- Mengras, Tel. Banera, Distt. Bhilwara, Rajasthan, 311408

DECLARATION

I solemnly declare that the above information is true and correct to the best of my knowledge.

Date: 11-03-2025
Place: Bhilwara



Signature